ES2619322T3 - Agente inductor de inmunidad - Google Patents

Agente inductor de inmunidad Download PDF

Info

Publication number
ES2619322T3
ES2619322T3 ES14185710.2T ES14185710T ES2619322T3 ES 2619322 T3 ES2619322 T3 ES 2619322T3 ES 14185710 T ES14185710 T ES 14185710T ES 2619322 T3 ES2619322 T3 ES 2619322T3
Authority
ES
Spain
Prior art keywords
polypeptide
immunity inducing
agent
inducing agent
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14185710.2T
Other languages
English (en)
Inventor
Fumiyoshi Okano
Masaki Shimizu
Takanori Saito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Application granted granted Critical
Publication of ES2619322T3 publication Critical patent/ES2619322T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un agente para su uso como agente inductor de inmunidad en el tratamiento o la prevencion de cancer animal, comprendiendo el agente, como principio activo, al menos un polipeptido que tiene actividad inductora de inmunidad y seleccionado de los siguientes polipeptidos (a), (b) y (c), o un vector recombinante que comprende un polinucleotido que codifica dicho polipeptido y capaz de expresar dicho polipeptido in vivo: (a) un polipeptido que tiene la secuencia de aminoacidos mostrada por cualquier SEC ID de numero par seleccionada de las SEQ ID NO: 2 a 30 en el listado de secuencias; (b) un polipeptido que tiene el 80 % o mas de identidad de secuencia con el polipeptido (a); y (c) un polipeptido que comprende los polipeptidos (a) o (b).

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20

Claims (1)

  1. imagen1
    imagen2
ES14185710.2T 2008-08-05 2009-08-05 Agente inductor de inmunidad Active ES2619322T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008202065 2008-08-05
JP2008202065 2008-08-05

Publications (1)

Publication Number Publication Date
ES2619322T3 true ES2619322T3 (es) 2017-06-26

Family

ID=41663742

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09805008.1T Active ES2539603T3 (es) 2008-08-05 2009-08-05 Agente inductor de inmunidad
ES14185710.2T Active ES2619322T3 (es) 2008-08-05 2009-08-05 Agente inductor de inmunidad

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES09805008.1T Active ES2539603T3 (es) 2008-08-05 2009-08-05 Agente inductor de inmunidad

Country Status (16)

Country Link
US (2) US8454968B2 (es)
EP (2) EP2324842B1 (es)
JP (2) JP5691171B2 (es)
KR (3) KR20160127146A (es)
CN (2) CN102112146B (es)
AU (2) AU2009278385B2 (es)
BR (2) BRPI0912462B1 (es)
CA (1) CA2732283C (es)
DK (2) DK2837383T3 (es)
ES (2) ES2539603T3 (es)
HU (1) HUE031343T2 (es)
MX (2) MX348464B (es)
PL (2) PL2324842T3 (es)
PT (2) PT2837383T (es)
RU (2) RU2511039C2 (es)
WO (1) WO2010016525A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101638490B1 (ko) 2008-08-05 2016-07-11 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
BRPI0911925B8 (pt) 2008-08-05 2024-02-06 Toray Industries Método para detectar um câncer
MX340015B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
BR112012018943A8 (pt) * 2010-02-04 2017-12-19 Toray Industries medicamento e método para o tratamento e/ou prevenção de um câncer
HUE025678T2 (en) 2010-02-04 2016-04-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
MX342291B (es) * 2010-02-04 2016-09-23 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
RU2598258C2 (ru) * 2010-02-04 2016-09-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
KR101842893B1 (ko) 2010-02-04 2018-03-28 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
WO2012157737A1 (ja) * 2011-05-19 2012-11-22 東レ株式会社 免疫誘導剤
BR112014002616B1 (pt) * 2011-08-04 2022-01-18 Toray Industries, Inc Método para detectar câncer pancreático
JP6070191B2 (ja) * 2011-08-04 2017-02-01 東レ株式会社 癌の治療及び／又は予防用医薬組成物
RU2595400C2 (ru) * 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2740794T (pt) * 2011-08-04 2018-06-14 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
KR102041832B1 (ko) 2011-08-04 2019-11-08 도레이 카부시키가이샤 췌장암의 치료 및/또는 예방용 의약 조성물
PT2740793T (pt) * 2011-08-04 2018-02-23 Toray Industries Composição de fármacos para o tratamento e/ou a prevenção de cancro
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
US9260513B2 (en) 2012-02-21 2016-02-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
HUE044611T2 (hu) 2012-02-21 2019-11-28 Toray Industries Gyógyászati készítmény rák kezelésére
PT2818483T (pt) 2012-02-21 2017-10-09 Toray Industries Composição medicinal para tratamento e/ou prevenção de cancro
KR102155531B1 (ko) 2012-03-30 2020-09-15 도레이 카부시키가이샤 간암의 치료 및/또는 예방용 의약 조성물
PT2832366T (pt) * 2012-03-30 2018-01-25 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar
RU2646466C2 (ru) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Метод детекции рака
PL2876447T3 (pl) 2012-07-19 2020-05-18 Toray Industries, Inc. Sposób wykrywania nowotworu
ES2704909T3 (es) 2013-08-09 2019-03-20 Toray Industries Composición farmacéutica para el tratamiento y/o la prevención del cáncer
WO2016175309A1 (ja) * 2015-04-30 2016-11-03 東レ株式会社 免疫誘導剤
KR20240005247A (ko) * 2016-10-28 2024-01-11 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
JP7342701B2 (ja) * 2018-03-30 2023-09-12 東レ株式会社 癌の治療及び／又は予防用医薬組成物
CN109206502B (zh) * 2018-09-26 2022-03-04 东北农业大学 一种猫干扰素ω及其制备方法和在抗病毒中的应用
CN109206501B (zh) * 2018-09-26 2022-03-04 东北农业大学 猫干扰素ω、其编码基因及其在抗病毒方面的应用
US20210404921A1 (en) * 2020-06-26 2021-12-30 Phaim Pharma Ltd Psoriasis and other autoimmune diseases antigen immune modulator (aim) therapeutic platform

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
CN100419079C (zh) * 1998-07-14 2008-09-17 科里克萨有限公司 用于治疗和诊断前列腺癌的组合物和方法
WO2002083070A2 (en) * 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
US20030190640A1 (en) * 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
JP4533626B2 (ja) * 2001-11-07 2010-09-01 サイトス バイオテクノロジー アーゲー アレルギー性好酸球性疾患を治療するための抗原アレイ
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20060121029A1 (en) * 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
EP1991701A4 (en) 2006-02-14 2010-03-17 Dana Farber Cancer Inst Inc COMPOSITIONS, KITS AND METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
KR20080075722A (ko) 2007-02-13 2008-08-19 엘지이노텍 주식회사 튜너
JP4826496B2 (ja) 2007-02-16 2011-11-30 三菱マテリアル株式会社 電解メッキ用アノード電極取付構造
WO2013143026A1 (en) * 2012-03-31 2013-10-03 Abmart (Shanghai) Co., Ltd Peptide and antibody libraries and uses thereof
EP3004141A4 (en) * 2013-06-03 2017-05-31 Acetylon Pharmaceuticals, Inc. Histone deacetylase ( hdac) biomarkers in multiple myeloma

Also Published As

Publication number Publication date
BRPI0912462A2 (es) 2016-02-02
PL2837383T3 (pl) 2017-07-31
JPWO2010016525A1 (ja) 2012-01-26
CN103751771B (zh) 2017-09-08
DK2324842T3 (da) 2015-06-22
JP5962739B2 (ja) 2016-08-03
RU2013156620A (ru) 2015-06-27
AU2009278385A1 (en) 2010-02-11
EP2324842B1 (en) 2015-03-25
US20130230488A1 (en) 2013-09-05
BR122020027042B1 (pt) 2022-11-08
RU2639518C2 (ru) 2017-12-21
JP2015061847A (ja) 2015-04-02
CN102112146A (zh) 2011-06-29
DK2837383T3 (en) 2017-03-20
US8454968B2 (en) 2013-06-04
AU2015210461A1 (en) 2015-09-03
KR20110044854A (ko) 2011-05-02
PT2324842E (pt) 2015-07-21
RU2511039C2 (ru) 2014-04-10
EP2837383A1 (en) 2015-02-18
ES2539603T3 (es) 2015-07-02
CN103751771A (zh) 2014-04-30
HUE031343T2 (hu) 2017-07-28
EP2324842A4 (en) 2012-05-23
MX348464B (es) 2017-06-14
EP2837383B1 (en) 2016-12-14
WO2010016525A1 (ja) 2010-02-11
CN102112146B (zh) 2014-03-12
KR102009241B1 (ko) 2019-08-09
PL2324842T3 (pl) 2015-08-31
CA2732283C (en) 2017-12-05
BRPI0912462B1 (pt) 2022-03-22
KR20170128637A (ko) 2017-11-22
RU2011108315A (ru) 2012-09-10
CA2732283A1 (en) 2010-02-11
AU2009278385B2 (en) 2015-06-11
PT2837383T (pt) 2017-03-17
US20110123492A1 (en) 2011-05-26
KR20160127146A (ko) 2016-11-02
MX2011001113A (es) 2011-03-04
KR101669827B1 (ko) 2016-10-27
MX339277B (es) 2016-05-19
EP2324842A1 (en) 2011-05-25
AU2015210461B2 (en) 2017-07-13
JP5691171B2 (ja) 2015-04-01
US9592281B2 (en) 2017-03-14

Similar Documents

Publication Publication Date Title
ES2619322T3 (es) Agente inductor de inmunidad
ES2541217T3 (es) Diferenciación de células madre mesenquimales
ES2512141T3 (es) Análogo peptídico de oxintomodulina
ES2540858T3 (es) Composición farmacéutica para el tratamiento y/o la prevención de cáncer
MX383887B (es) Composiciones farmacéuticas y uso de las mismas para la prevención y el tratamiento de cardiomiopatía asociada a la ataxia de friedreich.
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
CL2015002968A1 (es) Tratamiento combinado (por ejemplo con abt-072 o abt-333) de agentes antivirales de acción directa (daas) para uso en el tratamiento de hcv.
AR080658A1 (es) Toxinas insecticidas cry dig-5 de bacillus thuringiensis
ES2565060T3 (es) Polipéptidos que tienen actividad de glucoamilasa y polinucleótidos que codifican los mismos
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
CO2020008308A2 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
NZ736516A (en) Methods of tissue repair and regeneration
PE20130041A1 (es) Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
CO2018012258A2 (es) Compuestos de mic-1 y usos de estos
AR126239A1 (es) Región 5’ no traducida y región 3’ no traducida no naturales y uso de estas
ES2524251T3 (es) Proteínas de tipo interferón humano recombinantes
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
MX390157B (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
MY177369A (en) Reducing proinflammatory response
AR083126A1 (es) Composicion vacunal para el control de las infestaciones por ectoparasitos
ES2609817T3 (es) Leucotoxina E/D como nuevo agente antiinflamatorio y microbicida
ES2534752T3 (es) Nuevo péptido antigénico contra el cáncer y utilización del mismo
ES2605171T3 (es) Composiciones ansiolíticas que comprenden péptidos derivados de la Caseína ALFAs1